| Drug Name |
Bosutinib |
| Drug ID |
BADD_D00286 |
| Description |
Bosutinib is a Bcr-Abl kinase inhibitor for the treatment of Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML). Compared to other tyrosine kinase inhibitors, it has a more favourable hematologic toxicity profile. FDA approved on September 4, 2012. |
| Indications and Usage |
Treatment of chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance or intolerance to prior therapy in adult patients. |
| Marketing Status |
approved |
| ATC Code |
L01EA04 |
| DrugBank ID |
DB06616
|
| KEGG ID |
D03252
|
| MeSH ID |
C471992
|
| PubChem ID |
5328940
|
| TTD Drug ID |
D0OB0F
|
| NDC Product Code |
54893-0042; 54893-0041; 54893-0048; 63539-193; 63539-117 |
| UNII |
5018V4AEZ0
|
| Synonyms |
bosutinib | SKI606 | SKI-606 |
